Re-defining tigecycline therapy

New Microbiologica

Volumn 38, Issue 2, 2015, Pages 121-136

  De Rosa, Francesco G ^a   Corcione, Silvia ^a   Di Perri, Giovanni ^a   Scaglione, Francesco ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Broad spectrum antibacterial therapy; Complicated intra abdominal infections,Glycylcyclines; Complicated skin and soft tissue infections; Tigecycline

Indexed keywords

IAIS; NEGIBACTERIA; POSIBACTERIA;

ANTIINFECTIVE AGENT; MINOCYCLINE; TIGECYCLINE;

ANALOGS AND DERIVATIVES; BACTERIAL INFECTIONS; BACTERIUM; DRUG EFFECTS; HUMAN; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; HUMANS; MINOCYCLINE;

EID: 84930980729     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Anthony K.B., Fishman N.O., Linkin D.R., Gasink L.B., Edelstein P.H., Lautenbach E. (2008). Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin. Infect. Dis. 46, 567-570.
2. Babinchak T., Ellis-Grosse E., Dartois N., Rose G.M., Loh E. Tigecycline 301 Study Group; Tigecycline 306 Study Group. (2005). The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41, S354-367.
3. Bassetti M., Eckmann C., Bodmann K.F., Dupont H., Heizmann W.R., Montravers P., Guirao X., Cap-Parella M.R., Simoneau D., Sánchez García M. (2013). Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies. J. Antimicrob. Chemother. 68, 5-14.
4. Bassetti M., Poulakou G., Giamarellou H. (2014). Is there a future for tigecycline? Intensive Care Med. 40, 1039-1045.
5. Breedt J., Teras J., Gardovskis J., Maritz F.J., Vaas-Na T., Ross D.P., Gioud-Paquet M., Dartois N., Ellis-Grosse E.J., Loh E. Tigecycline 305 Csssi Study Group. (2005). Safety and efficacy of tige-cycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Anti-microb Agents Chemother. 49, 4658-4666.
6. Bhattacharya M., Parakh A., Narang M. (2009). Tige-cycline. J. Postgrad Med. 55, 65-68.
7. Bhattacharya I., Gotfried M.H., Ji A.J., Saunders J.P., Gourley I., Diehl A., Korth-Bradley J.M. (2014). Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. J. Clin. Pharmacol. 54, 70-74.
8. Bhavnani S.M., Rubino C.M., Ambrose P.G., Babinchak T.J., Korth-Bradley J.M., Drusano G.L. (2010). Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections. Antimicrob. Agents Chemother. 54, 1207-1212.
9. Bradford P.A., Weaver-Sands D.T., Petersen P.J. (2005). In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated in-tra-abdominal infections. Clin. Infect. Dis. 41, S315-332.
10. Cai Y., Wang R., Liang B., Bai N., Liu Y. (2011). Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob. Agents Chemother. 55, 1162-1172.
11. Canton R., Akova M., Carmeli Y., Giske C.G., Glupczynski Y., Gniadkowski M., Livermore D.M., Miriagou V., Naas T., Rossolini G.M., Samuelsen Ø., Seifert H., Woodford N., Nordmann P.; European Network On Carbapenemases. (2012). Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 18, 413-431.
12. Chen Z., Wu J., Zhang Y., Wei J., Leng X., Bi J., Li R., Yan L., Quan Z., Chen X., Yu Y., Wu Z., Liu D., Ma X., Maroko R., Cooper A. (2010). Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. BMC Infect. Dis. 10, 217.
13. Chuang Y.C., Cheng C.Y., Sheng W.H., Sun H.Y., Wang J.T., Chen Y.C., Chang S.C. (2014). Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by mul-tidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect. Dis. 14, 102.
14. Curcio D., Fernandez F., Vergara J., Vazquez W., Luna C.M. (2009). Late onset ventilator-associated pneumonia due to multidrug-resistant Acineto-bacter spp.: experience with tigecycline. J. Che-mother. 21, 58-62.
15. De Pascale G., Montini L., Pennisi M., Bernini V., Maviglia R., Bello G., Spanu T., Tumbarello M., Antonelli M. (2014). High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit. Care. 18, R90.
16. Dixit D, Madduri R.P., Sharma R. (2014). The role of tigecycline in the treatment of infections in light of the new black box warning. Expert Rev. Anti Infect. Ther. 12, 397-400.
17. Dryden M. (2013). Tigecycline: an antibiotic for the twenty-first century. J. Antimicrob. Chemother. 68, 3-4.
18. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., Loh E. (2005). Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 41, S341-353.
19. Esposito S., Bassetti M., Borre S., Bouza E., Dryden M., Fantoni M., Gould I.M., Leoncini F., Leone S., Milkovich G., Nathwani D., Segreti J., Sganga G., Unal S., Venditti M.; Italian Society Of Infectious Tropical Diseases; International Society Of Chemotherapy. (2011). Diagnosis and management of skin and soft-tissue infections (SSTI): a literature review and consensus statement on behalf of the Italian Society of Infectious Diseases and International Society of Chemotherapy. J. Chemother. 23, 251-262.
20. European Medicines Agency (EMA). (2011). Questions and answers on the review of Tygacil (tige-cycline): Outcome of a renewal procedure. Available at http://www.ema.europa.eu/ema/. Accessed 14 July 2014.
21. European Medicines Agency (EMA). (2014). Tygacil (tigecycline): EPAR-Summary of product characteristics. Available at http://www.ema.europa. eu/ema/. Accessed 14 July 2014.
22. Fda. (2010). FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. Available at http://www.fda.gov/drugs/drugsafety/ucm224370.htm. Accessed 14 July 2014.
23. Fda. (2013). FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. Available at http://www.fda.gov/Drugs/DrugSafety/ucm369580.htm. Accessed 14 July 2014.
24. Freire A.T., Melnyk V., Kim M.J., Datsenko O., Dz-Yublik O., Glumcher F., Chuang Y.C., Maroko R.T., Dukart G., Cooper C.A., Korth-Bradley J.M., Dartois N., Gandjini H. 311 Study Group. (2010). Comparison of tigecycline with imipenem/cilas-tatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 68, 140-151.
25. Gallagher J.C., Rouse H.M. (2008). Tigecycline for the treatment of Acinetobacter infections: a case series. Ann. Pharmacother. 42, 1188-1194.
26. Garau J. (2008). Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin. Microbiol. Infect. 14, 198-202.
27. Gordon N.C, Wareham D.W. (2009). A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resis-tant Acinetobacter baumannii with tigecycline. J. Antimicrob. Chemother. 63, 775-770.
28. Greer N.D. (2006). Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 19, 155-161.
29. Guner R., Hasanoglu I., Keske S., Kalem A.K., Tas-Yaran M.A. (2011). Outcomes in patients infected with carbapenem-resistant Acinetobacter bau-mannii and treated with tigecycline alone or in combination therapy. Infection. 39, 515-518.
30. Hirsch E.B., Tam V.H. (2010). Detection and treatment options for Klebsiella pneumoniae car-bapenemases (KPCs): an emerging cause of multidrug-resistant infection. J. Antimicrob. Che-mother. 65, 1119-1125.
31. Jamal W., Salama M., Dehrab N., Al Hashem G., Sha-Hin M., Rotimi V.O. (2009). Role of tigecycline in the control of a carbapenem-resistant Acineto-bacter baumannii outbreak in an intensive care unit. J. Hosp. Infect. 72, 234-242.
32. Kaewpoowat Q., Ostrosky-Zeichner L. (2015). Tigecycline: a critical safety review. Expert Opin. Drug. Saf. 14, 335-342.
33. Kim N.H., Hwang J.H., Song K.H., Choe P.G., Kim E.S., Park S.W., Kim H.B., Kim N.J., Park W.B., Oh M.D. (2013). Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome. Scand. J. Infect. Dis. 45, 315-319.
34. Ku K., Pogue J.M., Moshos J., Bheemreddy S., Wang Y., Bhargava A., Campbell M., Khandker N., Le-Phart P.R., Chopra T., Hayakawa K., Martin E.T., Abreu-Lanfranco O., Dhar S., Kaye K.S., Mar-Chaim D. (2012). Retrospective evaluation of colis-tin versus tigecycline for the treatment of Acine-tobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am. J. Infect. Control. 40, 983-987.
35. Kuo S.C., Wang F.D., Fung C.P., Chen L.Y., Chen S.J., Chiang M.C., Hsu S.F., Liu C.Y. (2011). Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients. J. Microbiol. Immunol. Infect. 441, 45-51.
36. Lee Y.T., Tsao S.M., Hsueh P.R. (2013). Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-re-sistant Acinetobacter baumannii infections. Eur. J. Clin. Microbiol. Infect. Dis. 32, 1211-1220.
37. Livermore D.M. (2005). Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemoth-er. 56, 611-614.
38. Mcgovern P., Babinchak T., Quintana A. (2011). Clarification to the systematic review and meta-anal-ysis involving tigecycline. Antimicrob. Agents Chemother. 55, 4941.
39. Meagher A.K., Passarell J.A., Cirincione B.B., Van Wart S.A., Liolios K., Babinchak T., Ellis-Grosse E.J., Ambrose P.G. (2007). Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother. 51, 1939-1945.
40. Metan G., Alp E., Yildiz O., Percin D., Aygen B., Sum-Erkan B. (2010). Clinical experience with tigecy-cline in the treatment of carbapenem-resistant Acinetobacter infections. J. Chemother. 22, 110-114.
41. Michail G., Labrou M., Pitiriga V., Manousaka S., Sa-Kellaridis N., Tsakris A., Pournaras S. (2013). Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob. Agents Chemo-ther. 57, 6028-6033.
42. Montravers P., Bassetti M., Dupont H., Eckmann C., Heizmann W.R., Guirao X., García M.S., Capparel-La M.R., Simoneau D., Bodmann K.F. (2013). Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. J. Antimicrob. Chemother. 68, 15-24.
43. Montravers P., Dupont H., Bedos J.P., Bret P. Tigecy-Cline Group. (2014). Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting. Intensive Care Med. 40, 988-997.
44. Moon S.Y., Peck K.R., Chang H.H., Kim S.W., Heo S.T., Son J.S., Ryu S.Y., Moon C., Jung S.I., Shin S.Y., Lee J.A., Joung M.K., Chung D.R., Kang C.I., Song J.H. (2012). Clinical experience of tigecy-cline treatment in infections caused by extensively drug-resistant Acinetobacter spp. Microb. Drug Resist. 18, 562-566.
45. Muralidharan G., Micalizzi M., Speth J., Raible D., Troy S. (2005). Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 49, 220-229.
46. Pai M.P. (2014). Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. J. Antimicrob. Chemother. 69, 190-199.
47. Pankey G.A. (2005). Tigecycline. J. Antimicrob. Chemother. 56, 470-480.
48. Passarell J.A., Meagher A.K., Liolios K., Cirincione B.B., Van Wart S.A., Babinchak T., Ellis-Grosse E.J., Ambrose P.G. (2008). Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimi-crob. Agents Chemother. 52, 204-210.
49. Piantadosi S. (2000). Clinical Trials: A Methodologic Perspective (First Edition). Wiley Online Library.
50. Postier R.G., Green S.L., Klein S.R., Ellis-Grosse E.J., Loh E. Tigecycline 200 Study Group. (2004). Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecy-cline for complicated skin and skin-structure infections in hospitalized patients. Clin. Ther. 26, 704-714.
51. Poulakou G., Kontopidou F.V., Paramythiotou E., Kompoti M., Katsiari M., Mainas E., Nicolaou C., Yphantis D., Antoniadou A., Trikka-Graphakos E., Roussou Z., Clouva P., Maguina N., Kanellakopou-Lou K., Armaganidis A., Giamarellou H. (2009). Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J. Infect. 58, 273-284.
52. Prasad P., Sun J., Danner R.L., Natanson C. (2012). Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin. Infect. Dis. 54, 1699-1709.
53. Ramirez J., Dartois N., Gandjini H., Yan J.L., Kor-Th-Bradley J., Mcgovern P.C. (2013). Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob. Agents Chemo-ther. 57, 1756-1762.
54. Rocchetti A., Zotti C.M., Argentero P.A., Raso R., Biglino A., Livigni S., Romagnoli S., Corcione S., De Rosa F.G., Ghisetti V. (2014). Epidemiology of carbapenemase-producing Klebsiella pneumo-niae in a north-west Italian region: report from the regional surveillance system. 24th European Society of Clinical Microbiology and Infectious Diseases (ECCMID) Meeting. Barcelona, Spain.
55. Rodvold K.A., Gotfried M.H., Cwik M., Korth-Brad-Ley J.M., Dukart G., Ellis-Grosse E.J. (2006). Serum, tissue and body fluid concentrations of tige-cycline after a single 100 mg dose. J. Antimicrob. Chemother. 58, 1221-1229.
56. Sartelli M., Viale P., Koike K., Pea F., Tumietto F., Van Goor H., Guercioni G., Nespoli A., Tranà C., Catena F., Ansaloni L., Leppaniemi A., Biffl W., Moore F.A., Poggetti R., Pinna A.D., Moore E.E. (2011). WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. World J. Emerg. Surg. 6, 2.
57. Sbrana F., Malacarne P., Viaggi B., Costanzo S., Leon-Etti P., Leonildi A., Casini B., Tascini C., Men-Ichetti F. (2013). Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneu-moniae in intensive care unit. Clin. Infect. Dis. 56, 697-700.
58. Scaglione F. (2011). Comment on: Efficacy and safety of tigecycline: a systematic review and meta-anal-ysis. J. Antimicrob. Chemother. 66, 2892-3; author reply 2895-2896.
59. Schafer J.J., Goff D.A., Stevenson K.B., Mangino J.E. (2007). Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter bau-mannii. Pharmacotherapy. 27, 980-987.
60. Solomkin J.S., Mazuski J.E., Bradley J.S., Rodvold K.A., Goldstein E.J., Baron E.J., O'neill P.J., Chow A.W., Dellinger E.P., Eachempati S.R., Gorbach S., Hilfiker M., May A.K., Nathens A.B., Sawyer R.G., Bartlett J.G. (2010). Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin. Infect. Dis. 50, 133-164.
61. Stein G.E., Smith C.L., Missavage A., Saunders J.P., Nicolau D.P., Battjes S.M., Kepros J.P. (2011). Tigecycline penetration into skin and soft tissue. Surg. Infect. (Larchmt). 12, 465-467.
62. Stevens D.L., Bisno A.L., Chambers H.F., Dellinger E.P., Goldstein E.J., Gorbach S.L., Hirschmann J.V., Kaplan S.L., Montoya J.G., Wade J.C. (2014). Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 59, e10-52.
63. Swoboda S., Ober M., Hainer C., Lichtenstern C., Seiler C., Wendt C., Hoppe-Tichy T., Büchler M., Weigand M.A. (2008). Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J. Antimicrob. Chemother. 61, 729-33.
64. Sun H.K., Ong C.T., Umer A., Harper D., Troy S., Nightingale C.H., Nicolau D.P. (2005). Pharmaco-kinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob. Agents Chemother. 49, 1629-1632.
65. Tacconelli E., Cataldo M.A., Dancer S.J., De Ange-Lis G., Falcone M., Frank U., Kahlmeter G., Pan A., Petrosillo N., Rodríguez-Baño J., Singh N., Venditti M., Yokoe D.S., Cookson B. European Society Of Clinical Microbiology. (2014). ESCMID guidelines for the management of the infection control measures to reduce transmission of mul-tidrug-resistant Gram-negative bacteria in hospitalized patients. Clin. Microbiol. Infect. 20, 1-55.
66. Tanaseanu C., Bergallo C., Teglia O., Jasovich A., Oliva M.E., Dukart G., Dartois N., Cooper C.A., Gandjini H., Mallick R. 308 Study Group; 313 Study Group. (2008). Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn. Mi-crobiol. Infect. Dis. 61, 329-338.
67. Tasina E., Haidich A.B., Kokkali S., Arvanitidou M. (2011). Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect. Dis. 11, 834-844.
68. Theriot C.M., Schumacher C.A., Bassis C.M., Seekatz A.M., Young V.B. (2014). The Effects of Tigecy-cline and Vancomycin Administration on Established C. difficile Infection. Antimicrob. Agents Chemother. [Epub ahead of print].
69. Vasilev K., Reshedko G., Orasan R., Sanchez M., Te-Ras J., Babinchak T., Dukart G., Cooper A., Dartois N., Gandjini H., Orrico R., Ellis-Grosse E. 309 Study Group. (2008). A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter bauman-nii and Klebsiella pneumoniae. J. Antimicrob. Chemother. 62, i29-40.
70. Van Ogtrop M.L., Andes D., Stamstad T.J., Conklin B., Weiss W.J., Craig W.A., Vesga O. (2000). In vivo pharmacodynamic activities of two glycylcy-clines (GAR-936 and WAY 152, 288) against various gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 44, 943-949.
71. Wiskirchen D.E., Koomanachai P., Nicasio A.M., Nicolau D.P., Kuti J.L. (2011). In vitro pharma-codynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Antimicrob. Agents Chemother. 55, 1420-1427.
72. Yahav D., Lador A., Paul M., Leibovici L. (2011). Efficacy and safety of tigecycline: a systematic review and meta-analysis. J. Antimicrob. Chemother. 66, 1963-19671.
73. Ye J.J., Lin H.S., Kuo A.J., Leu H.S., Chiang P.C., Huang C.T., Lee M.H. (2011). The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-re-sistant Acinetobacter baumannii. J. Infect. 63, 351-361.
74. Zhanel G.G., Karlowsky J.A., Rubinstein E., Hoban D.J. (2006). Tigecycline: a novel glycylcycline antibiotic. Expert Rev. Anti Infect. Ther. 4, 9-25.
75. Zhang Q., Zhou S., Zhou J. (2014). Tigecycline treatment causes a decrease in fibrinogen levels. J. Antimicrob. Agents Chemother. [Epub ahead of print].